TICKERNOMICS Sign up
Last Update: 2024-12-27 15:29:07
Athira Pharma Inc. ( ATHA ) https://www.athira.com
0.54USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-78.11%
ATHA
SPY
32.66%
-95.69%
ATHA
SPY
108.59%
ATHA
0.00%
SPY
302.52%
ATHA
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
19.76
-47.78
0.59
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.18
11.93
0.34
-567.65
0.00
0.42
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-1671.92
-14.61
-1720.82
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.32
-110.82
-62.46
0.00
Other Earnings and Cash Flow Stats:
Athira Pharma Inc. ( ATHA ) Net Income TTM ($MM) is -109.22
Athira Pharma Inc. ( ATHA ) Operating Income TTM ($MM) is -115.98
Athira Pharma Inc. ( ATHA ) Owners' Earnings Annual ($MM) is 0.00
Athira Pharma Inc. ( ATHA ) Current Price to Owners' Earnings ratio is 0.00
Athira Pharma Inc. ( ATHA ) EBITDA TTM ($MM) is -115.01
Athira Pharma Inc. ( ATHA ) EBITDA Margin is -1720.82%
Capital Allocation:
Athira Pharma Inc. ( ATHA ) has paid 0.00 dividends per share and bought back -0.463019 million shares in the past 12 months
Athira Pharma Inc. ( ATHA ) has reduced its debt by 0.358 million USD in the last 12 months
Capital Structure:
Athira Pharma Inc. ( ATHA ) Interest-bearing Debt ($MM) as of last quarter is 1
Athira Pharma Inc. ( ATHA ) Annual Working Capital Investments ($MM) are -24
Athira Pharma Inc. ( ATHA ) Book Value ($MM) as of last quarter is 57
Athira Pharma Inc. ( ATHA ) Debt/Capital as of last quarter is 2%
Other Balance Sheet Stats:
Athira Pharma Inc. ( ATHA ) has 68 million in cash on hand as of last quarter
Athira Pharma Inc. ( ATHA ) has 27 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Athira Pharma Inc. ( ATHA ) has 38 common shares outstanding as of last quarter
Athira Pharma Inc. ( ATHA ) has 0 million USD of preferred stock value
Academic Scores:
Athira Pharma Inc. ( ATHA ) Altman Z-Score is -9.50 as of last quarter
Athira Pharma Inc. ( ATHA ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Athira Pharma Inc. ( ATHA ) largest shareholder is owning shares at 0.00 ($MM) value
Gengos Andrew(an insider) Sold 1272 shares of Athira Pharma Inc. ( ATHA ) for the amount of $719.95 on 2024-09-05
1.95% of Athira Pharma Inc. ( ATHA ) is held by insiders, and 62.14% is held by institutions
Athira Pharma Inc. ( ATHA ) went public on 2020-09-18
Other Athira Pharma Inc. ( ATHA ) financial metrics:
FCF:-97.54
Unlevered Free Cash Flow:0.00
EPS:-2.98
Operating Margin:-1671.92
Gross Profit Margin:-14.61
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-199.65
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Athira Pharma Inc. ( ATHA ) :
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is ATH-1017 Fosgonimeton, a small molecule designed to enhance the activity of hepatocyte growth factor (HGF) and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an orally available, brain-penetrant small molecule positive modulator of HGF/MET which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.